Uppsala,
Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a clinical trial application for a phase 2a trial has now been submitted. It is a so-called "proof of concept", with the main objective of demonstrating that LIB-01 can improve erectile function in patients with erectile dysfunction. The trial, which is placebo-controlled and double-blind, will include approximately 140 participants and will be conducted at clinics in
"We continue to focus on driving the drug development of LIB-01 forward. With the submitted clinical trial application and the capital secured from the upcoming rights issue we can continue to maintain a high pace and in accordance with our schedule. We are very much looking forward to starting this exciting development phase and to keeping you updated with information about the study", comments
For further information, please contact:
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-pharma-ab/r/dicot-pharma-has-submitted-clinical-trial-application-for-phase-2a-trial,c4012432
https://mb.cision.com/Main/17172/4012432/2905967.pdf
(c) 2024 Cision. All rights reserved., source